What is Desloratadin Cipla?
Desloratadin Cipla is an antihistamine that reduces the effects of the natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.
Desloratadin Cipla is used to treat the symptoms of allergies, such as sneezing, watery eyes, and runny nose. It is also used to treat skin hives and itching in people with chronic skin reactions.
Desloratadin Cipla may also be used for purposes not listed in this medication guide.
Desloratadin Cipla indications
1.1 Seasonal Allergic Rhinitis
Desloratadin Cipla Tablets are indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age and older.
1.2 Perennial Allergic Rhinitis
Desloratadin Cipla Tablets are indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 12 years of age and older.
1.3 Chronic Idiopathic Urticaria
Desloratadin Cipla Tablets are indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 12 years of age and older.
How should I use Desloratadin Cipla?
Use Desloratadin Cipla orally disintegrating tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Desloratadin Cipla orally disintegrating tablets. Talk to your pharmacist if you have questions about this information.
- Take Desloratadin Cipla orally disintegrating tablets by mouth with or without food.
- Do not remove the blister from the outer pouch until you are ready to take Desloratadin Cipla orally disintegrating tablets. Make sure that your hands are dry when you open the blister pack. Do not push the tablet through the foil. Peel back the foil on the blister pack and place the tablet on your tongue. The tablet dissolves quickly and can be swallowed with saliva. Desloratadin Cipla orally disintegrating tablets may be taken with or without water. Take the tablet immediately after opening the blister pack. Do not store the removed tablet for future use.
- If you miss a dose of Desloratadin Cipla orally disintegrating tablets and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Desloratadin Cipla orally disintegrating tablets.
Uses of Desloratadin Cipla in details
Use: Labeled Indications
Allergic rhinitis: Relief of nasal and non-nasal symptoms of seasonal (SAR) and perennial (PAR) allergic rhinitis
Urticaria: Symptomatic relief of pruritus, reduction in number of hives, and reduction in size of hives associated with chronic idiopathic urticaria (CIU)
Off Label Uses
NSAID-associated urticaria (prophylaxis)
Data from a retrospective study with a limited number of patients suggest that Desloratadin Cipla may be beneficial for prophylactic therapy in patients with NSAID-associated urticaria prior to receiving a strong COX-1 inhibitor. Additional trials may be needed to further define the role of Desloratadin Cipla in this setting.
Desloratadin Cipla description
Desloratadin Cipla Tab: Each tablet contains 5.0 mg of Desloratadin Cipla.
Desloratadin Cipla Syr: Each mL of Desloratadin Cipla syrup contains 500 mcg of Desloratadin Cipla.
Excipients/Inactive Ingredients: Desloratadin Cipla Tab: Dibasic calcium phosphate dihydrate, microcrystalline cellulose, maize starch, talc, blue color film-coat material, clear film coat material, white wax and carnauba wax.
Desloratadin Cipla dosage
Desloratadin Cipla Dosage
Generic name: Desloratadin Cipla 5mg
Dosage form: tablet, film coated; oral solution
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Although an orally disintegrating tablet formulation of Desloratadin Cipla may be available in the marketplace, Desloratadin Cipla® RediTabs® Tablets are no longer marketed.
Desloratadin Cipla Tablets,
Oral Solution, or RediTabs Tablets may be taken without regard to meals. Place Desloratadin Cipla (Desloratadin Cipla) RediTabs Tablets on the tongue and allow to disintegrate before swallowing. Tablet disintegration occurs rapidly. Administer with or without water. Take tablet immediately after opening the blister.
The age-appropriate dose of Desloratadin Cipla
Oral Solution should be administered with a commercially available measuring dropper or syringe that is calibrated to deliver 2 mL and 2.5 mL (½ teaspoon).
Adults and Adolescents 12 Years of Age and Over
The recommended dose of Desloratadin Cipla Tablets or Desloratadin Cipla Tablets is one 5-mg tablet once daily. The recommended dose of Desloratadin Cipla
Oral Solution is 2 teaspoonfuls (5 mg in 10 mL) once daily.
Children 6 to 11 Years of Age
The recommended dose of Desloratadin Cipla
Oral Solution is 1 teaspoonful (2.5 mg in 5 mL) once daily. The recommended dose of Desloratadin Cipla Tablets is one 2.5-mg tablet once daily.
Children 12 Months to 5 Years of Age
The recommended dose of Desloratadin Cipla
Oral Solution is ½ teaspoonful (1.25 mg in 2.5 mL) once daily.
Children 6 to 11 Months of Age
The recommended dose of Desloratadin Cipla
Oral Solution is 2 mL (1 mg) once daily.
Adults with Hepatic or Renal Impairment
In adult patients with liver or renal impairment, a starting dose of one 5-mg tablet every other day is recommended based on pharmacokinetic data. Dosing recommendation for children with liver or renal impairment cannot be made due to lack of data.
More about Desloratadin Cipla (Desloratadin Cipla)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 5 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Desloratadin Cipla
- Desloratadin Cipla syrup
- Desloratadin Cipla (Advanced Reading)
Professional resources
- Desloratadin Cipla (AHFS Monograph)
- Desloratadin Cipla (FDA)
Other formulations
- Desloratadin Cipla-D 24 Hour
- Desloratadin Cipla-D 12 Hour
- Desloratadin Cipla
Related treatment guides
- Allergic Rhinitis
- Urticaria
Desloratadin Cipla interactions
See also:
What other drugs will affect Desloratadin Cipla?
Inhibitors Of Cytochrome P450 3A4
In controlled clinical studies co-administration of Desloratadin Cipla with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of Desloratadin Cipla and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of Desloratadin Cipla.
Fluoxetine
In controlled clinical studies co-administration of Desloratadin Cipla with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of Desloratadin Cipla and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of Desloratadin Cipla.
Cimetidine
In controlled clinical studies co-administration of Desloratadin Cipla with cimetidine, a histamine H2-receptor antagonist, resulted in increased plasma concentrations of Desloratadin Cipla and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of Desloratadin Cipla.
Drug Abuse And Dependence
There is no information to indicate that abuse or dependency occurs with Desloratadin Cipla Tablets.
Desloratadin Cipla side effects
See also:
What are the possible side effects of Desloratadin Cipla?
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Desloratadin Cipla tablets were reported in 3 % of patients in excess of those treated with placebo. The most frequent adverse events reported in excess of placebo were fatigue (1.2 %), dry mouth (0.8 %), and headache (0.6 %).
Very rare cases of hypersensitivity reactions (including anaphylaxis and rash) tachycardia, palpitations, psychomotor hyperactivity, seizures, elevations of liver enzymes, hepatitis, and increased bilirubin have been reported during the marketing of Desloratadin Cipla.
Desloratadin Cipla Syr: In clinical trials in a paediatric population, Desloratadin Cipla Syrup was administered to a total of 246 children aged 6 months through 11 years. The overall incidence of adverse events in children 2 through 11 years of age was similar for Desloratadin Cipla Syrup and the placebo groups. In infants and toddlers aged 6 to 23 months, the most frequent adverse events reported in excess of placebo were diarrhea (3.7%), fever (2.3%) and insomnia (2.3%).
Desloratadin Cipla contraindications
See also:
What is the most important information I should know about Desloratadin Cipla?
You should not take this medication if you are allergic to Desloratadin Cipla or to loratadine (Claritin).
Before taking Desloratadin Cipla, tell your doctor if you are allergic to any drugs, or if you have liver or kidney disease.
Do not give this medication to a child younger than 2 years old without the advice of a doctor.
Desloratadin Cipla disintegrating tablets (Desloratadin Cipla) may contain phenylalanine. Talk to your doctor before using this form of Desloratadin Cipla if you have phenylketonuria (PKU).
Active ingredient matches for Desloratadin Cipla:
Desloratadine in Croatia (Hrvatska).
References
- DailyMed. "DESLORATADINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "Desloratadine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Desloratadine". http://www.drugbank.ca/drugs/DB00967 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Desloratadin Cipla are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Desloratadin Cipla. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
